BRAF and thyroid gland carcinoma: Numerous studies have demonstrated that TERT promoter mutations, especially when accompanied with BRAF V600E or RAS mutations, showed strong correlation to aggressive clinical characteristics, radioiodine refractory and poor clinical outcomes in patients with thyroid cancer (12–19).